Nonalcoholic Fatty Liver Disease.

Nonalcoholic fatty liver disease (NAFLD) is considered the hepatic manifestation of the metabolic syndrome (MetS) and comprises one of the largest health threats of the twenty-first century. In this chapter, we review the current state of knowledge of NAFLD and underline the striking similarities with atherosclerosis. We first describe current epidemiological data showing the staggering increase of NAFLD numbers and its related clinical and economic costs. We then provide an overview of pathophysiological hepatic processes in NAFLD and highlight the systemic aspects of NAFLD that point toward metabolic crosstalk between organs as an important cause of metabolic disease. Finally, we end by highlighting the currently investigated therapeutic approaches for NAFLD, which also show strong similarities with a range of treatment options for atherosclerosis.

the systemic aspects of NAFLD that point toward metabolic crosstalk between organs as an important cause of metabolic disease. Finally, we end by highlighting the currently investigated therapeutic approaches for NAFLD, which also show strong similarities with a range of treatment options for atherosclerosis.

Keywords
Atherosclerosis · Epidemiology · NAFLD · Pathogenesis · Treatment Abbreviations ALT Alanine transaminase ASK1 Apoptosis signal-regulating kinase 1 CCR2/CCR5 C-C chemokine receptor type 2/C-C chemokine receptor 5 CKD Chronic kidney disease CPT- Being the most prevalent chronic liver disease worldwide (Li et al. 2019), nonalcoholic fatty liver disease (NAFLD) covers a diseases spectrum, initiating with hepatic steatosis which is defined by the presence of !5% hepatic fat (referred to steatosis) in the absence of any secondary cause of hepatic steatosis such as chronic viral hepatitis and alcohol consumption (21 drinks/week in men and 14 drinks/week in women) (Chalasani et al. 2012(Chalasani et al. , 2018. In a second, more advanced stage, hepatic steatosis may advance into nonalcoholic steatohepatitis (NASH), which is characterized by a combination of hepatic steatosis and inflammation in the presence or absence of fibrosis. Finally, NASH can progress into advanced-stage liver diseases such as cirrhosis and hepatocellular carcinoma (HCC) (Angulo 2002;Anstee and Day 2013;Calzadilla Bertot and Adams 2016;Chalasani et al. 2018;Fazel et al. 2016;Jou et al. 2008;Sayiner et al. 2016;Younossi and Henry 2016;Younossi et al. 2018a). Being the hepatic component of the metabolic syndrome (MetS) (Chalasani et al. 2012), NAFLD is commonly associated with other metabolic disorders such as obesity, which is also linked to the development of cardiovascular diseases such as atherosclerosis (Chalasani et al. 2018;Paoletti et al. 2006). Considering these links between NAFLD, obesity, and atherosclerosis, it is no surprise that NAFLD has become the most prevalent liver disease worldwide (Li et al. 2019). Indeed, in the last three decades, the prevalence of NAFLD has increased at a constant rate. Numbers from a study from Younossi et al. showed the evolution of NAFLD prevalence in the United States from 1988 to 2008 ranging from 5.51% (1988)(1989)(1990)(1991)(1992)(1993)(1994) to 9. 84% (1999-2004) and 11.01% (2005)(2006)(2007)(2008), indicating a twofold increase over two decades (Younossi et al. 2011a). At a global level, it is currently estimated that NAFLD affects about 25% of the general population. At the other hand, NASH has been calculated at 2-5% of the general population and so far represents the minority of NAFLD patients (10-20%) (Younossi et al. 2016a). However, while hepatic steatosis seems less harmful for the liver, patients suffering from steatosis are at increased risk for cardiac-related death (Targher et al. 2016). Therefore, steatotic patients should be monitored even at an early stage of the disease. For the future, Estes et al. predicted the NAFLD population to increase with 21% in 2030, expecting a staggering 100.9 million NAFLD patients, of which 27.00 million patients would also suffer from NASH, the latter indicating a 63% increase in prevalence compared to current numbers (Estes et al. 2018). From a regional perspective, the pooled incidence of NAFLD in the West (being Europe and Northern America) was estimated to be 28 per 1,000 persons per year (Chalasani et al. 2018;Younossi et al. 2016b). As mentioned previously, NAFLD has been reported as the most common liver disease in the United States (Bellentani and Marino 2009). However, within the Asian population, recent metadata also indicated the global incidence rate of NAFLD at 50.9 cases per 1,000 individuals per year (Li et al. 2019). Indeed, while it was initially perceived as a "Western disease," NAFLD is now highly prevalent in all continents with the highest rates reported in South America (31%) and the Middle East (32%), followed by Asia (27%), the United States (24%), and Europe (23%), while being less common in Africa (14%) (Younossi et al. 2016b).
Taken these numbers into account, and especially those indicating the exponential increase of NASH patients, it is clear that NAFLD poses one of the largest burdens on current healthcare systems, emphasizing the urge for early and fast treatment to prevent further escalation of this disease.

Association with Other Diseases
NAFLD has been reported to be strongly linked to obesity, with a prevalence as high as 80% in obese patients and only 16% in individuals with a normal BMI and without metabolic risk factors (Bellentani et al. 2000;Williams et al. 2011). Relevantly, obesity seems to play a role in both the initial process leading to simple steatosis but also to its progression toward NASH (Polyzos et al. 2017). Indeed, it has been demonstrated that the risk of NASH development is lower in lean than overweight/obese individuals (Sookoian and Pirola 2018). Next to NASH, also patients suffering from hepatic fibrosis tend to be rather obese than non-obese (86% vs. 27%, respectively) (Fassio et al. 2004). Besides obesity, it has been suggested that NAFLD is also tightly linked to cardiovascular diseases (Patil and Sood 2017). Recently, clinical observations indicated that NASH increases atherosclerosis and cardiovascular risks by local overexpression of inflammatory mediators, endothelial damage, and regulators of blood pressure (Targher et al. 2009(Targher et al. , 2010. Others confirmed that NAFLD is independently associated with atherosclerosis progression (Targher et al. 2010). Additionally, other studies demonstrated that NAFLD patients have impaired flow-mediated vasodilatation (Villanova et al. 2005), increased carotid artery intimal-medial thickness and an increased prevalence of carotid atherosclerotic plaques compared to healthy subjects (Sookoian and Pirola 2008), independently of obesity and other established risk factors. These observations therefore emphasize the link between NAFLD and atherosclerosis.
Additionally, NAFLD has also been suggested as a risk factor for gastrointestinal tract malignancies, such as colorectal cancer (Lindenmeyer and McCullough 2018;Muhidin et al. 2012;Wong et al. 2011). Also, NAFLD is also associated with chronic kidney disease (CKD) (Musso et al. 2014), which is defined by the presence of kidney damage or a reduced glomerular filtration rate for 3 months or more (Levey et al. 2005). Specifically, it has been suggested that the prevalence of CKD in NAFLD patients is between 4 and 40% (Marcuccilli and Chonchol 2016). This association has been partly explained by the NAFLD-associated microvascular alterations that also affect the kidney (Musso et al. 2016). Moreover these microvascular alterations have been linked to cerebrovascular disease, potentially contributing to cognitive impairment (Lombardi et al. 2019). Finally, polycystic ovary syndrome (PCOS), a condition that leads to the production of higher-thannormal amounts of male hormones in women, is also associated with NAFLD (Vassilatou 2014;Wu et al. 2018a). However, the clinical significance and its pathophysiological basis remain to be further investigated.

1.3
Clinical, Economic, and Social Burden of NAFLD In spite of its increased prevalence over the last decades, to our knowledge, the clinical burden of NAFLD has not been characterized in detail (Boursier et al. 2018;Lam et al. 2016;Mullerova et al. 2019;Welte et al. 2012). Notwithstanding that all stages of NAFLD contribute to its clinical burden, the more progressive stages of NALFD are expected to have the largest impact .
As a progressive form of NAFLD, NASH is currently the second leading cause for liver transplantation in the United States and even the leading cause for liver transplantation in females (Noureddin et al. 2018). Furthermore, it is known that NAFLD has become one of the leading causes for cirrhosis (Kadayifci et al. 2008), the end-stage liver disease which is associated with high risks for development of bacterial infections leading to hospitalization (Albillos et al. 2014;Li et al. 2018;Singal et al. 2014). Additionally, the presence of advanced fibrosis (stage !2) in NAFLD has been directly associated with liver-related mortality (Angulo et al. 2015;Younossi et al. 2011b). There is also accumulating evidence that NAFLD is an important risk factor for hepatocellular carcinoma (HCC), which is the fifth most common type of cancer and third most common cause of cancer mortality (El-Serag and Rudolph 2007;Piscaglia et al. 2016;Younossi et al. 2015a). Translating the latter described observations into exact numbers, a recent study showed that in 2015, 28,000 deaths (2.2% of all deaths in the NAFLD population) were related to cirrhosis, HCC, or liver transplantation, while 162,560 deaths (accounting for 12.8% of all NAFLD deaths) were due to cardiovascular diseases (Angulo et al. 2015;Ekstedt et al. 2015). Indeed, these data point toward an important role for cardiovascular diseases in NAFLD-related mortality. In line with the previously estimated increased prevalence of NAFLD in the future, reports have indicated that the total number of deaths resulting from NAFLD will increase 44%, reaching 1.83 million deaths at an annual basis by 2030 (Estes et al. 2018). Regarding to the healthcare expenditure, Lam et al. demonstrated that more frequent clinical visits are associated with improved outcomes in pediatric NAFLD patients, substantiating the importance of frequent monitoring and follow-up to manage NAFLD progression (Lam et al. 2016). Moreover, Boursier et al. evaluated the hospitalization of NAFLD-/NASH-related end-stage liver disease (ESLD) patients by a 7-year follow-up study in France. This report described that ESLD patients experience more hospitalization per year (over 400%), which are longer (400% increase in length) and are associated with a 300% increase in hospitalization costs (Boursier et al. 2018). These numbers therefore indicate the gigantic investments that are required to manage NAFLD. In line with the increasing prevalence of NAFLD, the economic costs related to NAFLD have also been predicted to rise in the future. In the United States alone, approximately 103 billion dollars are annually spent on NAFLD-related costs, while in European countries (i.e., France, the United Kingdom, Germany, and Italy), these costs account for approximately €35 billion (Abdelmalek 2016). Of particular concern is the rising prevalence of obesity as well as the increase in general healthcare costs, which contributes to a tenfold increase in the current economic burden of NAFLD by 2025 (Abdelmalek 2016;Younossi et al. 2016a). Several studies also investigated the relationship between NAFLD patients and healthcare utilization and associated costs. These studies demonstrated that the number of outpatient visits for patients with NAFLD significantly doubled over time and underlined the fact that, between 2005 and 2010, the healthcare costs of inpatients and outpatients were increased 5% and 10%, respectively (Baumeister et al. 2008;Younossi et al. 2014Younossi et al. , 2015b. Additionally, a study of the hepatology clinics in the West Suffolk area of the United Kingdom showed that the total annual hepatology budget for these specialized clinics was £130,000, including £58,000 for resources and £72,000 for clinic attendances. Moreover, the latest research estimating the economic burden of NASH patients by using a Markov decision analytic model demonstrated that lifetime costs of all NASH patients was approximately $222.6 billion in the United States in 2017, with $95.4 billion reflecting the advanced NASH population (Younossi et al. 2019).
From an individual perspective, NALFD patients have to contend with a range of symptoms such as fatigue, decreased physical activity, and emotional health impairment which affect their quality of life (health-related quality of life (HR-QOL)) (Golabi et al. 2016;Loria et al. 2013;Henry 2015, 2016). Several studies have demonstrated that NAFLD patients had poorer HR-QOL compared to other chronic liver diseases and also showed that NAFLD-related fatigue associated with impairments in physical functioning (Afendy et al. 2009;Dan et al. 2007;Newton et al. 2008). Potential explanations for the decrease of HR-QOL in NAFLD patients that have been raised are related to obesity and psychological processes as well as psychiatric issues such as depression and anxiety (Stewart and Levenson 2012;Surdea-Blaga and Dumitrascu 2011;Weinstein et al. 2011). Indeed, several studies have demonstrated that depressive disorders, as well as anxiety disorders, are more frequent in patients with NAFLD/NASH and are associated with more advanced liver histological abnormalities, such as severe hepatocyte ballooning (Elwing et al. 2006;Macavei et al. 2016;Stewart et al. 2015;Weinstein et al. 2011).
Altogether, these numbers substantiate the impact of NAFLD on healthcare, economy, and also the daily life of individual patients. To prevent further escalation of the disease, it is therefore of utmost importance to increase the understanding of the disease to find approaches to diagnose and treat (and if possible prevent) the progression of NAFLD.

Pathophysiology of NAFLD
As NAFLD comprises a spectrum of diseases, multiple pathophysiological processes are involved including dysregulation of lipid metabolism, increased hepatic inflammation, and the presence of hepatic fibrosis. However, how patients with steatosis develop inflammation is still unclear, leaving a blind spot in the understanding of how NASH exactly arises. Nevertheless, scientists have succeeded in unraveling several disease processes in NALFD, which appear to show striking similarities with disease processes described in atherosclerosis. Furthermore, increasing evidence links different metabolic organs to NAFLD development, emphasizing the presence of metabolic crosstalk during NAFLD.

Intrahepatic Disturbances During NAFLD
The liver constitutes a key role in regulating whole body metabolism, which involves a complex interplay between different hepatic cell types ranging from hepatocytes as parenchymal cells to Kupffer cells (KCs), stellate cells, and liver sinusoidal endothelial cells (LSECs) among other cell types. As such, each of these cell types is influenced by pathophysiological processes during NAFLD, eventually leading to hepatic disturbances at whole organ level.

Lipo-and Glucotoxicity
Due to low physical activity and increased consumption of fats, lipotoxicity has arisen as one of the main players to contribute to NAFLD pathogenesis (Ibrahim et al. 2011). Lipotoxicity is defined by the excess generation of cytosolic lipids (mainly triglycerides and subtypes of free fatty acids) that have direct adverse effects on metabolic pathways of the cell (Schaffer 2016). Under normal conditions, triglycerides and free fatty acids are stored in adipose tissue, where they can be employed as energy source during periods of energy deprivation or during extreme exercise (Muro et al. 2014). However, in obesity, when the storage capacity of adipose tissue is exceeded, free fatty acids accumulate in ectopic organs, including the liver (but also in the arteries). As such, hepatic steatosis (Wojcik-Cichy et al. 2018) develops, resulting in the formation of adverse metabolites that hamper normal cellular physiology. For example, an excess of free fatty acids such as palmitic or stearic acids induces the generation of toxic metabolites, leading to caspase-dependent apoptosis of hepatocytes (Kakisaka et al. 2012;Pfaffenbach et al. 2010) but also of cardiomyocytes (Drosatos and Schulze 2013;Zou et al. 2017) and endothelial cells (Artwohl et al. 2008;Chinen et al. 2007). Indeed, while free fatty acid-induced apoptosis of hepatocytes is a key feature of lipotoxicity in the context of NAFLD (Trauner et al. 2010), other reports have shown that excess palmitate induces endoplasmic reticulum stress and apoptosis in the context of atherosclerosis as well (Erbay et al. 2009). Therefore, free fatty acid-induced apoptosis of parenchymal cells appears to be a shared mechanism between NAFLD and atherosclerosis development.
Besides inducing apoptosis, free fatty acid influx into hepatocytes also influences the function of key enzymes and nuclear receptors involved in hepatic de novo lipogenesis, fatty acid oxidation, and cholesterol metabolism, thereby further disturbing hepatic lipid metabolism. Indeed, expression levels of acetyl-coenzyme-A carboxylase 1, a key enzyme in fatty acid metabolism (Barber et al. 2005), were shown to decrease in advanced stages of NASH compared to individuals with steatosis (Nagaya et al. 2010). Moreover, in the transcriptional levels, liver X receptor (LXR), a nuclear receptor involved with regulation of cholesterol, fatty acid, and glucose metabolism (Kalaany and Mangelsdorf 2006), correlated with intrahepatic inflammation and fibrosis in NAFLD patients (Ahn et al. 2014;Ni et al. 2017). In line, macrophage-targeted delivery of LXR agonist inside the atherosclerotic plaque reduced atherosclerosis progression (Guo et al. 2018), pointing toward a key function of LXR in both NAFLD and atherosclerosis development.
Lipotoxic responses also affect LSECs, a type of non-parenchymal cell that is specifically involved in maintaining hepatic vascular tone and quiescence of hepatic stellate cells that are responsible for the fibrotic response. Upon treatment with oxidized lipids (Zhang et al. 2014) or palmitic acid (Matsumoto et al. 2018), LSCEs directly or indirectly triggered the release of reactive oxygen species (ROS) production (Peters et al. 2018), which influences mechanisms related to inflammation and fibrosis (Ni et al. 2017).
Increased hepatic fat accumulation has also been associated with reduced levels of high-density lipoproteins (HDL) and increased levels of total plasma cholesterol, low-density lipoproteins (LDL), and very low-density lipoprotein particles (Koruk et al. 2003), the latter being involved with hepatic lipid export. Moreover, besides triglycerides and fatty acids, it has become evident that cholesterol is a key player in inducing hepatic inflammatory responses (Caballero et al. 2009;Plat et al. 2014;van Rooyen et al. 2011). Indeed, in the context of obesity-associated diseases, it was shown that cholesterol levels are associated with hepatic inflammation (Musso et al. 2003;Puri et al. 2007) and atherosclerosis (Ference et al. 2017) in humans. In agreement with these data, it has previously been shown that omitting cholesterol from the diet was able to prevent liver inflammation in hyperlipidemic and atherosclerosis-prone mice (Wouters et al. 2008), pointing toward cholesterol as a significant risk factor for early onset of NASH and progression of atherosclerosis.
In addition to lipotoxicity, glucotoxicity is a metabolic condition linked to increased intake of dietary sugars, resulting in hyperglycemia which may cause hepatotoxic effects by increasing steatosis (Mota et al. 2016). For instance, it was shown that high carbohydrate intake plays a role in de novo lipogenesis and hepatic steatosis (Ackerman et al. 2005;Neuschwander-Tetri et al. 2012), presumably via activation of lipogenic enzymes such as fatty acid synthase and stearoyl-CoA desaturase-1 (Maslak et al. 2015). In addition, high-fructose intake was shown to correlate with the severity of fibrosis in NAFLD patients (Basaranoglu et al. 2015;Mota et al. 2016) and carbohydrate intake associated with the progression of coronary atherosclerosis (Mozaffarian et al. 2004).
Glucotoxic and lipotoxic products, including free fatty acids, cholesterol, and ceramides, among others (Han et al. 2008), are also involved in the activation of cellular stress responses. For instance, it has been shown that saturated long-chain fatty acids can disturb metabolic fluxes, thereby increasing the production of harmful lipid intermediates (Kakisaka et al. 2012). These intermediates can promote the release of ROS, leading to oxidative stress and hence the progression from steatosis to NASH (Matsuzawa et al. 2007;van Herpen and Schrauwen-Hinderling 2008) and the development of atherosclerosis (Nowak et al. 2017).
Overall, these evidences show that triglycerides, fatty acids, and cholesterol overload disturb essential processes in the liver that result in NAFLD features, placing lipids at the center of NAFLD development. Moreover, as these processes show striking similarities with disturbances present in atherosclerosis, lipotoxicity is a denominator linking NAFLD to atherosclerosis.

Oxidative Stress and Mitochondrial Dysfunction
As mentioned in the previous paragraph, part of the lipotoxic response involves the generation of ROS, resulting in oxidative stress. Oxidative stress comprises a state during which there is an imbalance between generation of ROS at one hand and an inability to detoxify (i.e., via antioxidant mechanisms) these oxygenated intermediates (Masarone et al. 2018). As a consequence, free radicals, peroxides, and related products are generated and react with biological components such as proteins, DNA, but also lipids (Finkel and Holbrook 2000). Indeed, considering the increased amount of lipids present during NAFLD conditions, larger quantities of lipid peroxidation products are present in the liver of NAFLD patients (Sumida et al. 2013) and contribute to the transition toward more serious stages of NAFLD (Busch et al. 2017;Feldstein et al. 2010). In addition, ROS is known to mediate endoplasmic reticulum stress, thereby causing the formation of misfolded proteins, which is a critical factor in NAFLD (Ashraf and Sheikh 2015) as well as the progression of atherosclerosis (Hotamisligil 2010;Tabas 2010). Moreover, cholesterol oxidation products that are part of oxidized low-density lipoproteins (oxLDL) are majorly involved in inflammatory and fibrotic responses in the liver (also further discussed in next section) .
Considering the key role of mitochondria in cellular oxygen consumption and production of ROS, lipotoxic influences on mitochondria have the potential to further aggravate oxidative stress (Dominguez-Perez et al. 2019). Under physiological conditions, fatty acid transport into the mitochondria is mediated via carnitine palmitoyltransferase 1 (CPT-1) in order to stimulate beta-oxidation. Nevertheless, the expression of Cpt-1 was shown to be reduced in NAFLD (Kohjima et al. 2007), findings that were further supported by Francque et al., showing that peroxisome proliferator-activated receptor alpha (PPARα), an important nuclear receptor regulating CPT-1, inversely correlated with disease severity in patients with NASH (Francque et al. 2015). By using isolated mitochondria, it was also shown that short chain ceramides increase mitochondrial permeability due to the generation of ceramide channels and increased cytochrome C release (Colombini 2010), thereby mediating toxic effects. Moreover, mitochondrial cholesterol accumulation caused mitochondrial dysfunction (Balboa et al. 2017), and based on studies in the context of neurotoxicity (Barbero-Camps et al. 2014), mitochondrial cholesterol may play a role in endoplasmic reticulum stress and subsequent apoptosis.

Hepatic Inflammation and Fibrosis
An essential pathophysiological process during NAFLD that also unites the lipotoxic response with the generation of oxidative stress is the presence of hepatic inflammation which can progress into hepatic fibrosis. In contrast to the uptake of non-modified LDL, it has been established that the uptake of oxLDL contributes to cholesterol-induced foam cell formation and metabolic inflammation (Lara-Guzman et al. 2018) in NASH (Houben et al. 2017) but also in the context of atherosclerosis (Binder et al. 2003). Moreover, the accumulation of oxidized lipids into the lysosomal compartment of macrophages activates inflammatory cascades including inflammasome complexes and apoptosis Grebe et al. 2018;Hendrikx et al. 2013;Jerome 2010). Indeed, recent studies show that specific inhibition of the NLRP3 inflammasome not only reverses hepatic inflammation and fibrosis (Mridha et al. 2017) but also reduces atherosclerotic lesion development (van der Heijden et al. 2017), pointing toward an important role for the inflammasome in chronic inflammatory diseases (Cai et al. 2017;Duewell et al. 2010;Pan et al. 2018). Furthermore, cholesterol-mediated activation of inflammasomes decreases cholesterol efflux, thereby disturbing the regulation of bile acid metabolism. Previously, it was indeed shown that mice lacking the bile acid receptor farnesoid X receptor (FXR) had pro-atherogenic lipoproteins (Mencarelli and Fiorucci 2010) and increased hepatic bile acid levels (Sinal et al. 2000), pointing toward a potential role for FXR in cholesterol-induced liver inflammation. Indeed, improving cholesterol efflux in hepatic macrophages by overexpressing Cyp27a1, an enzyme responsible for the conversion of cholesterol into bile acids, reduced hepatic inflammation and fibrosis in an experimental model (Hendrikx et al. 2015). Via accumulation of oxidized lipids into lysosomes, also disturbances in autophagy contribute to increased levels of inflammation both during NAFLD (Wu et al. 2018b) and atherosclerosis (Martinet and De Meyer 2009). Besides cholesterol, also other lipids such as phospholipids (Lee et al. 2012) and fatty acids (Reinaud et al. 1989), can (non)enzymatically interact with free radicals, triggering inflammation by a wide variety of underlying processes (Houben et al. 2017).
While macrophages play a key role in the inflammatory response, hepatic stellate cells are the main drivers of the fibrotic response (Friedman 1993). After a damaging insult, stellate cells are activated, thereby secreting collagens and related matrix proteins that lead to generation of scar tissue or fibrosis (Peters et al. 2018;Schneiderhan et al. 2001), a pathological process also described in atherosclerosis (Ostovaneh et al. 2018). Relevantly, Chu et al. recently demonstrated that exposing hepatic stellate cells to fatty acids resulted in an increased secretion of CCL20, resulting in a switch from a quiescent to an activated hepatic stellate cell. These findings were further confirmed in humans, showing increased circulating CCL20 protein levels in patients with NAFLD-related fibrosis (Chu et al. 2018). Further data based on an elegant co-culturing system using primary liver cells pointed toward CCL5 as an important hepatic stellate cell-derived chemokine capable of mediating steatosis and pro-inflammatory responses in initially healthy hepatocytes . Moreover, in vivo induction of CCL5 in response to high-fat diet was also shown to serve as an important regulator of vascular remodeling, revealing a role for CCL5 and its receptor in atherogenesis . Therefore, multiple reports indicate that lipids enable fibrotic responses by influencing hepatic stellate cells.

Metabolic Crosstalk in NAFLD
As previously mentioned, the capacity of adipose tissue to store lipids determines the quantity of free fatty acids to be released into the circulation under high lipid conditions. However, besides its storage capacity, adipose tissue is known as a "secretory" organ, releasing adipokines and adipocytokines that influence other organs (Ouchi et al. 2011). For this reason, lipid-induced adipose tissue function increases the release of adipocytokines such as TNFα, IL6, IL18, and ANGPTL, leading to inflammatory responses in other metabolic organs such as the liver (Ouchi et al. 2011;Reilly et al. 2015). Moreover, the release of these adipokines also influences circulating immune cells, contributing to a state of chronic inflammation (Bijnen et al. 2018;Mancuso 2016;Nakamura et al. 2014). Due to this systemic impact, it is not surprising that adipokines also influence atherosclerosis development. Indeed, adipose tissue-released TNFα directly influenced atherosclerosis development (Tanaka and Sata 2018). Besides modulating inflammation, the increased release of free fatty acids also hinders the anti-lipolytic role of insulin, aggravating insulin resistance (Engin 2017;Sears and Perry 2015). Another extrahepatic organ that has been linked to NAFLD development is the thyroid. Being an endocrine organ, the thyroid secretes hormones that have a role in the regulation of energy homeostasis including the metabolism of cholesterol and fatty acids (Sinha et al. 2018). Specifically, hypothyroidism is characterized by increased serum LDL and HDL levels and decreased triglyceride levels (Duntas 2002). Besides indirectly influencing hepatic lipid metabolism by modulating circulating lipid levels, thyroid hormones also directly affect hepatic lipid metabolism mainly via the presence of hepatic thyroid hormone receptors (THR) (Sinha et al. 2018). THRs are nuclear hormone receptors that function as ligand-dependent transcription factors influencing downstream metabolic genes (Davis et al. 2016) but also disturb other metabolic transcription factors such as PPARy, LXR, and sterol regulatory element-binding protein 1 (SREBP1c) (Araki et al. 2009;Wang et al. 2015). For this regulatory role on hepatic lipid metabolism, THR agonists were also considered for the management of hepatic steatosis (Cable et al. 2009) but later observed adverse effects resulted in discontinuation of these clinical trials (Lammel Lindemann and Webb 2016). Nevertheless, thyroid hormones analogues (rather than THRs) are still considered as potential future NAFLD treatment (Perra et al. 2008).
Another organ that has gained attention in the context of NAFLD is the brain. At one hand, NAFLD-related inflammation has been demonstrated to influence microglia in the brain, leading to alterations in microvasculature of the brain (Ghareeb et al. 2011;Kim et al. 2016). Furthermore, NAFLD-associated endothelial dysfunction and the procoagulant state were linked to the same microvascular alterations, which may contribute to disturbances in brain circulation, damage, and cognitive impairment (Lombardi et al. 2019). Besides the link to the aforementioned cerebrovascular diseases (Airaghi et al. 2018), other brain-related associations have been established to NAFLD. Firstly, a recent report from Horwath et al. demonstrated that endoplasmic reticulum stress in the subfornical organ of the brain, a brain region previously linked to appetite (Matsuda et al. 2017), directly mediated hepatic steatosis, thereby directly linking the brain to the liver in the context of NAFLD. Moreover, Weinstein et al. recently linked NAFLD to lower cerebral brain volume hinting at a more profound role for the brain in NAFLD (Weinstein et al. 2018). Finally, as a regulation center for energy metabolism, brain regions such as the arcuate nucleus in the hypothalamus sense the metabolic status and govern food intake (Schwartz et al. 2000), making an obvious link to obesity-related NAFLD. An essential hormone involved with the homeostatic regulation of energy and acting via the hypothalamus is leptin (Kwon et al. 2016). Notably, variants of leptin receptors associated with increased NAFLD susceptibility, pointing toward a potential role for hypothalamic leptin sensitivity in NAFLD (Zain et al. 2013). Additional evidence linking hypothalamic inflammation to hepatic steatosis further substantiated the potential involvement of the hypothalamus in NAFLD (Valdearcos et al. 2015).
To end, multiple reports have indicated the involvement of the gastrointestinal tract to play a role in NAFLD development. Under physiological circumstances, the intestinal lining serves as a physical barrier that separates the host from contents in the gut. Disruption of this barrier leads to intestinal permeability (Winer et al. 2016), allowing for leakage of intestinal bacteria and other products into the circulation. Indeed, leakage of lipopolysaccharide (LPS) derived from intestinal bacteria into the circulation (Kitabatake et al. 2017) can activate KCs in the liver (Ye et al. 2012), thereby directly resulting in NASH development (Kitabatake et al. 2017;Wigg et al. 2001). Relevantly, gut-derived serum LPS was similarly associated with atherosclerosis development, reaffirming the tight link between NASH and atherosclerosis (Pastori et al. 2017). Though there are limited studies providing a causal role of the gut microbiome in NAFLD pathogenesis, the current amount of evidence suggests that the gut microbiota are at least involved with the development of NAFLD (Gregory et al. 2015;Kaden-Volynets et al. 2018;Martinez-Guryn et al. 2018;Turnbaugh et al. 2006) . Other well-known factors linking the gut to NAFLD are bile acid metabolism (Dumas et al. 2006;Tremaroli and Backhed 2012), bacterial-derived short-chain fatty acids (Canfora et al. 2019), and the toxic compounds dimethylamine and trimethylamine that were converted by bacteria from choline (Spencer et al. 2011;Wang et al. 2011). In line with our other descriptions, each of these compounds has also been associated with atherosclerosis development (Chambers et al. 2018;Charach et al. 2018;Tang et al. 2013).
Based on these evidences, it is clear that the development of NAFLD is linked to pathophysiological processes that arise in other (metabolic) organs. This information fuels a view of NAFLD being a complex, systemic disease influenced by a range of other organs. It is therefore likely that future management of NAFLD will require a systemic rather than a liver-specific approach.

Genetic Predisposition to NAFLD
NAFLD is considered a polygenic disease, implying the involvement of a variety of genetic factors in predisposing individuals to disease onset. While mutations in the patatin-like phospholipase domain-containing 3 (PNPLA3) gene were initially associated with hepatic steatosis (Romeo et al. 2008), other reports have also correlated the PNPLA3 variation to NASH progression (BasuRay et al. 2019;Valenti et al. 2010). Similarly, PNPLA3 genetic variants are also associated with carotid atherosclerosis in younger patients NAFLD (Petta et al. 2013). Though PNPLA3 variants were recently linked to the ubiquitylation processes (BasuRay et al. 2017), the exact underlying mechanism explaining the onset of NAFLD is still unclear. Additionally, based on several population studies, it was recently described that mutations in the transmembrane 6 superfamily 2 (TM6SF2), a key regulator of very low-density lipoprotein (VLDL) export, correlated with NASH progression (Manne et al. 2018) and cardiovascular disease , most likely via changes in plasma lipids. Indeed, plasma lipids appear to be one of the common denominators predicting severity of both NAFLD and coronary artery disease (Brouwers et al. 2019).
Further genetic screenings for NAFLD revealed that glucokinase regulator (GCKR) (Santoro et al. 2012) and lysophospholipid acyltransferase 7 (known as MBOAT7) (Mancina et al. 2016), key enzymes for glucose metabolism and reacetylation of phospholipids, respectively, as well as neurocan were associated with NAFLD development (Speliotes et al. 2011). Yet, a more recent study focusing on the aforementioned NAFLD-risk alleles (PNPLA3, TM6SF2, GCKR, and LYPLAL1) substantiated the heterogeneity of the NAFLD phenotype between patients, emphasizing the complexity of the disease (Sliz et al. 2018). As such, though genetic predisposition may influence disease onset, other pathophysiological factors that are independent of genetic predisposition are likely a stronger contributor to explain NAFLD development.
A line of research that has received increased attention is the influence of epigenetic changes on NAFLD development (Eslam et al. 2018). Epigenetic changes are induced by modifications in the regulators of DNA such as DNA methylation reactions, histone proteins, chromatin structure, and RNA-based mechanisms resulting in changes in genes expression (Eslam et al. 2018). These epigenetic modifications influence aging-related processes which contribute to NALFD (Horvath et al. 2014) but can also be transmitted to the progeny, thereby combining genetic and environmental factors involved in the development of disease. Mice that were rechallenged with a high-fat diet after being exposed to this diet during fetal life showed more several hepatic steatosis, inflammation, and fibrosis (Bruce et al. 2009). This influence of a detrimental fetal environment on NAFLD has been further substantiated by studies linking intrauterine growth retardation to increased risk of developing NAFLD (Nobili et al. 2007;Suomela et al. 2016;Valenti and Romeo 2016). Furthermore, methylation patterns of genes involved insulin signaling associated with the presence of NASH, which disappeared after bariatric surgery (Ahrens et al. 2013). As such, though being in its infancy, epigenetic modifications are expected to have an important role on NAFLD progression (Eslam et al. 2018).

Therapeutics
The involvement of different mechanisms in the pathogenesis of NAFLD also adds a level of complexity in finding appropriate therapeutic options to improve the different aspects of NAFLD. While therapies to reduce hepatic steatosis are known, a major problem is reversing the inflammatory component in the liver. Indeed, at present, no effective therapeutic approaches exist for reducing hepatic inflammation (Houben et al. 2017). From market size perspective, NASH-related therapeutics generated $1,179 million in 2017 and is estimated to reach $21,478 million by 2025 (Shinde 2018), pointing toward the huge demand for NASH treatments. Due to the magnitude of this health concern and its potential impact on healthcare, multiple treatments are currently being investigated with the aim to decrease inflammation and fibrosis (Oh et al. 2016). In this section, we provide a selection of currently investigated therapeutic approaches for NAFLD and demonstrate that these approaches are also investigated in the context of atherosclerosis (see Fig. 1). From this perspective, we further highlight the link between NAFLD and atherosclerosis.

Dietary/Lifestyle Intervention and Bariatric Surgery
Dietary changes and lifestyle interventions resulting in weight reduction are currently the first-line therapy for NAFLD patients (Sumida and Yoneda 2018). Indeed, dietary restriction is the most effective way to reduce liver fat (Marchesini et al. 2016;Patel et al. 2015). Furthermore, it has been suggested that hepatic triglyceride content normalizes after a few weeks under a strictly hypocaloric diet (Patel et al. 2015), i.e., low fat and low carbohydrate, which has been proposed as the optimal composition of a diet for NAFLD patients (Asrih and Jornayvaz 2014). Apart from dietary changes, lifestyle modification is another way to lose weight, for instance, via physical activity instead of sedentariness (Fabricatore 2007). However, compared to dietary restriction, physical activity is less effective in losing weight due to reduced caloric consumption as compared with dietary restriction (Marchesini et al. 2016;Zou et al. 2018). While dietary change and lifestyle intervention are able to reduce body weight, many patients cannot adhere to these interventions. Therefore, bariatric surgery, and more recently termed metabolic surgery (Sasaki et al. 2014), typically results in massive weight loss and in concordant improvements in liver histology (Dixon et al. 2004). Indeed, Mummadi et al. reported that the resolution rates of steatosis, steatohepatitis, and fibrosis were 91.6%, 81.3%, and 65.5% in 15 studies using paired liver biopsies after bariatric surgery (Mummadi et al. 2008). Recently, a 1-year follow-up study by Nickel et al. also supported bariatric surgery as an effective treatment for NAFLD (Nickel et al. 2018). However, as not all NAFLD patients qualify for bariatric surgery, other interventions are necessary to combat NAFLD and related symptoms.

Targeting Lipotoxicity
As accumulation of lipids inside the liver comprises an essential component in the development of NAFLD, multiple therapeutic approaches have aimed to reduce hepatic lipids with the objective to concordantly reduce hepatic inflammation and fibrosis. The best known example of cholesterol-reducing agents are statins, which are drugs aimed at inhibiting 3-hydroxy-3-methylglutarylcoenzyme A (HmG-CoA) reductase, the rate-limiting enzyme in the cholesterol biosynthesis pathway (Stancu and Sima 2001). Showing beneficial results in the context of atherosclerosis (Bittencourt and Cerci 2015), statins were also investigated in Fig. 1 Targets for NAFLD therapy. Besides exercise, changing the dietary pattern or surgical intervention and pharmacological intervention to improve NAFLD targets the pathological mechanisms of lipotoxicity, insulin/glucose metabolism, hepatic inflammation, fibrosis, as well as bile acid metabolism. HmG-CoA 3-hydroxy-3-methylglutarylcoenzyme A, PPAR peroxisome proliferator-activated receptor, GLP1R glucagon-like peptide-1 receptor, DPP4 dipeptidyl peptidase-4, SGLT2 sodium-glucose transport protein 2, FXR farnesoid X receptor NAFLD progression. Though some improvements were observed in hepatic damage and inflammation (Kargiotis et al. 2014), other reports declare only minor improvements or even increasing levels of inflammation and fibrosis when statins are administered over a longer period of time (Hyogo et al. 2008). Moreover, recent observations pointing toward the detrimental effects of statins on aging and associated processes (Cholesterol Treatment Trialists 2019; Izadpanah et al. 2015) raise drawbacks for using these drugs under certain conditions. Finally, and potentially, the most promising pharmacological compound currently under investigation to regress NASH are agonists of PPAR. PPARs are nuclear receptor proteins exerting key regulatory functions as transcription factors on metabolism, among other physiological processes (Dubois et al. 2017). Currently, three types of PPARs (being PPARα, PPARβ/δ, and PPARγ) are known and used as targets to improve MetS-related symptoms. In the context of NAFLD, and specifically NASH, the PPARγ agonist class thiazolidinediones has been shown to improve hepatic inflammation and advanced fibrosis (Bril et al. 2018;Musso et al. 2017). Furthermore, a new agonist, named elafibranor (or GFT505) that targets PPARα and PPARδ, was recently shown to improve hepatic inflammation and fibrosis, along with improvements in systemic inflammation, lipid, and glucose metabolism (Ratziu et al. 2016;Staels et al. 2013).
Due to these positive results, both thiazolidinediones and elafibranor are currently under clinical investigation for the treatment of NASH (Connolly et al. 2018). With regard to their application in atherosclerosis, thiazolidinediones have also been proven to slow progression of atherosclerosis in patients (Saremi et al. 2013), while elafibranor was so far not tested in this context. However, preliminary results in an atherosclerotic mouse model suggest that this latter PPARα/δ dual agonist might also be beneficial in the context of atherosclerosis (Graham et al. 2005).
Besides pharmacological intervention, a more convenient manner of reducing lipids is by means of dietary intervention. Apart from following dietary regimens in which the composition of lipids, protein, and carbohydrates is modulated and caloric intake is minimized (Ratziu et al. 2015) in order to achieve improvements in energy metabolism (Kargulewicz et al. 2014;Perumpail et al. 2017), another approach is to increase the intake of food components named functional foods. Plant sterol and stanol esters are examples of such functional foods that have been proven to reduce serum total and LDL cholesterol (Lichtenstein and Deckelbaum 2001;Plat et al. 2019), leading to improvements in atherosclerosis (Kohler et al. 2017) and NAFLD (Plat et al. 2014). However, more studies are necessary to prove the potential benefit of plant sterol and stanol esters in NAFLD patients.

Targeting Insulin/Glucose Metabolism
As diabetes has been associated with several stages of NAFLD , researchers have investigated the impact of improving insulin and glucose metabolism in order to improve aspects of NAFLD. Firstly, glucagon-like peptide-1 receptor (GLP1R) agonists, which mimic the function of incretins, are currently investigated in NAFLD (Gastaldelli and Marchesini 2016). GLP is a peptide derived from the L cells of the lower gastrointestinal tract (the small intestine and proximal colon) and known to enhance insulin secretion from pancreatic β cells and inhibit glucagon release from pancreatic α cells (Campbell and Drucker 2013;Ratziu et al. 2015). Whereas the GLP1R agonist exenatide enhanced hepatic steatosis (Tanaka et al. 2014), hepatic oxidative stress, and hepatic inflammation (Shao et al. 2018) and improved adipose tissue lipolysis in different in vivo models, the application of dulaglutide, lixisenatide, liraglutide, and, recently, semaglutide also shows promising results in terms of improvements in hepatic fat, damage, inflammation, and fibrosis (Armstrong et al. 2016;Cusi et al. 2018;Ipsen et al. 2018;Koutsovasilis et al. 2018;Petit et al. 2017;Rakipovski et al. 2018). As such, liraglutide (Armstrong et al. 2016) and semaglutide were under extensive clinical investigation. While liraglutide will not be further evaluated in phase 3 development, Novo Nordisk has initiated a phase 2b trial (NCT02970942) evaluating semaglutide versus placebo in 372 participants with stage F2-F3 fibrosis and NAS !4 with a score of at least 1 for each of the components (steatosis, ballooning, and lobular inflammation) (Connolly et al. 2018). Relevantly, as diabetes has also been linked to formation and progression of the atherosclerotic plaque (Beckman et al. 2002;Chait and Bornfeldt 2009;Katakami 2018), several GLP1R agonists have also been shown to improve atherosclerosis including exenatide, liraglutide, and semaglutide Marso et al. 2013;Rakipovski et al. 2018;Yang et al. 2017).
Besides the GLRP1 agonists, another approach to improve the GLP1-related effects on insulin and glucose metabolism is by administration of dipeptidyl peptidase-4 (DPP4) inhibitors. DPP4 (also referred to as CD26) is an enzyme known to degrade GLP1. Hence, inhibition of DPP4 enhances the activity of GLP1. While administration of the DPP4 inhibitor sitagliptin has been successfully applied in diabetic patients (Derosa et al. 2015;Drucker and Nauck 2006), several reports demonstrated only minor to no beneficial effects on hepatic fat content or hepatic fibrosis (Cui et al. 2016;Joy et al. 2017). Relevantly, these negative results in the context of NAFLD were also confirmed in atherosclerosis, showing only minor effects on coronary artery plaque improvement Nozue et al. 2016).
Another class of pharmacological compounds that specifically improve glucose metabolism is inhibitors for sodium-glucose transport protein 2 (SGLT2), a transporter protein in the kidney responsible for the reabsorption of glucose (Hsia et al. 2017;Marshall 2018;van Baar et al. 2018). In contrast to the minor effects of the DPP4 inhibitors on NAFLD, the SGLT2 inhibitors canagliflozin, ipragliflozin, and luseogliflozin all show substantial improvements in hepatic steatosis, apoptosis, and fibrosis in in vivo models and NAFLD patients (Ito et al. 2017;Kabil and Mahmoud 2018;Shiba et al. 2018;Shibuya et al. 2018;Sumida et al. 2019). In line with the previously described similarities between NAFLD and atherosclerosis, SGLT2 inhibitors were shown to also positively impact atherosclerosis progression and development (Nakatsu et al. 2017;Nasiri-Ansari et al. 2018;Tanaka et al. 2016;Zelniker et al. 2019).
Together, several treatments aimed at improving insulin or glucose metabolism have positive effects on several aspects of NAFLD, substantiating the role of insulin and glucose metabolism in the progression of NAFLD. Moreover, therapeutic products that improve features of NAFLD also positively impact atherosclerosis, providing further evidence for the similarities between NAFLD and atherosclerosis.

Targeting Hepatic Inflammation and Fibrosis
Another therapeutic approach to ameliorate NAFLD is to directly target components of the inflammatory and/or fibrotic pathway, as these features are the main cause for hepatic symptoms in NAFLD patients and are also responsible for the development toward advanced liver diseases (Schuster et al. 2018). The caspase inhibitor, emricasan, is one of those investigated compounds targeting the inflammatory aspect of NAFLD. Specifically, caspases are enzymes involved with several physiological processes including inflammation, making them an attractive inflammatory drug target. Administration of emricasan to NAFLD patients showed improvements in hepatic damage (as evidenced by reductions in alanine transaminase (ALT) levels) ). However, recent negative results with this compound have questioned its continuation for further clinical investigation (Garcia-Tsao et al. 2019). Another potential caspase-related target for inflammatory drugs is blocking the activation of inflammasomes (Schuster et al. 2018). Indeed, inhibition of the P2X7 receptor, which is known to activate the NLRP3 inflammasome (Amores-Iniesta et al. 2017), via SGM-1019 resulted in improvements in hepatic inflammation and fibrosis in mouse models and NASH patients (Dabbagh et al. 2018), substantiating its further clinical investigation in NAFLD. Another way to reduce inflammation and fibrosis is by blocking the effect of cytokines and chemokines that propagate the inflammatory reaction. With this regard, the C-C chemokine receptor type 2/C-C chemokine receptor 5 (CCR2/CCR5) inhibitor cenicriviroc has been successfully created. Specifically, cenicriviroc reduced hepatic fibrosis, inflammation, as well as systemic inflammatory parameters in NAFLD patients and animal models (Friedman et al. 2018;Lefebvre et al. 2016;Tacke 2018). Currently, cenicriviroc is being evaluated in phase 3 trials, targeting patients with F2-F3 fibrosis and having an anticipated enrollment of 2,000 participants (Connolly et al. 2018). Additionally, inhibition of galectin-3, a protein belonging to the lectin family and previously linked to NASH severity, has provided promising first results , which need to be further validated. Finally, inhibition of apoptosis signalregulating kinase 1 (ASK1) has also been investigated as drug target to reduce hepatic inflammation and fibrosis. ASK1 is part of the mitogen-activated protein kinase family and has been shown an essential role in NASH development in patients and mouse models Xiang et al. 2016;Zhang et al. 2018). In line with this observation, inhibition of ASK1 using selonsertib has shown impressive improvements in hepatic inflammation and fibrosis (Loomba et al. 2017;Younossi et al. 2018b). Selonsertib is currently under evaluation in two phase 3 clinical trials (STELLAR-3 [NCT03053050] and STELLAR-4 [NCT03053063]) for the treatment of NASH (Connolly et al. 2018).
Similar to the dual therapeutic effects of approaches targeting insulin and glucose metabolism, therapeutic approaches targeting inflammation and fibrosis also show dual positive influences in atherosclerosis and NASH. Galectin-3 has, for example, been linked atherosclerotic plaque progression (Papaspyridonos et al. 2008), and its inhibition results in reductions of atherosclerotic lesion size in vivo (MacKinnon et al. 2013). However, compared to drugs targeting insulin and glucose metabolism, targeting inflammation and fibrosis pathways is less investigated in the context of atherosclerosis, as exemplified by no described clinical studies for selonsertib, emricasan, ASK1 inhibitors, or cenicriviroc.

Targeting Bile Acid Metabolism
Hepatic components that have been extensively linked to different aspects of NAFLD include bile acids. Bile acids have regulatory functions on lipid and glucose metabolism, impact gut microbiota composition, and influence hepatic inflammation and damage (Schuster et al. 2018), explaining why modulation of bile acid metabolism has been an attractive therapeutic target for NAFLD. Firstly, the hepatoprotective natural bile acid ursodeoxycholic acid (UDCA) has been shown to exert beneficial effects on immune function, has anti-apoptotic and insulin-sensitizing effects, and reduces harmful effects of reactive oxygen species (Kars et al. 2010;Ljubuncic et al. 1996;Rodrigues et al. 1998), all aspects present during NAFLD. Indeed, besides improvements in hepatic steatosis, inflammation, and damage in NASH animal models, two randomized controlled trials showed improvements in lobular inflammation and hepatic fibrosis along with reductions in ALT levels upon UDCA administration (Leuschner et al. 2010;Ratziu et al. 2011). However, other studies showed no effect of UDCA administration in NASH patients (Liechti and Dufour 2012), emphasizing the need for further investigation. In addition, agonists of FXR, a nuclear receptor that has been linked to NAFLD (Zhang et al. 2009), have also been tested in NAFLD. Obeticholic acid (OCA), a semisynthetic variant of chenodeoxycholic acid, showed reductions in steatosis and fibrosis (Fiorucci et al. 2005;Goto et al. 2018), and recently, the first promising results were published from the FLINT study, investigated OCA in NAFLD patients (Neuschwander-Tetri et al. 2015). Currently, OCA is being evaluated in the phase 3 study REGENERATE (NCT02548351) for the treatment of NASH (Connolly et al. 2018). Strikingly, though bile acids are produced by the liver, multiple evidences have pointed toward their systemic effects on inflammation, cell death, and apoptosis (Chiang 2013). As such, recent evidences have also shown beneficial effects of UDCA (Bode et al. 2016) and OCA (Hageman et al. 2010;Moris et al. 2017) in atherosclerotic models.

Conclusion
As the hepatic component of the MetS, NAFLD comprises one of the largest global health threats of the twenty-first century. Though the exact etiology of why NAFLD patients progress from hepatic steatosis to hepatic inflammation and fibrosis is unclear, several studies have established key pathophysiological processes contributing to hepatic inflammation. Considering this large amount of processes involved with NAFLD (which have intra-and extrahepatic origins), it is clear that NAFLD is a complex, systemic disease with high interindividual variation, pointing toward combination therapies or personalized medicine as potential future directions for NAFLD. Moreover, due to this systemic nature, it is clear that NAFLD and atherosclerosis are very closely linked (Bieghs et al. 2012), implying the liver as a potential target to manage atherosclerosis.